A Phase I, Open Label Study To Evaluate The Safety, Pharmacokinetic, Pharmacodynamic And Clinical Activity Of Pf-06863135, A B-cell Maturation Antigen (Bcma)-cd3 Bispecific Antibody, In Patients With Relapsed/Refractory Advanced Multiple Myeloma (mm)

Trial Profile

A Phase I, Open Label Study To Evaluate The Safety, Pharmacokinetic, Pharmacodynamic And Clinical Activity Of Pf-06863135, A B-cell Maturation Antigen (Bcma)-cd3 Bispecific Antibody, In Patients With Relapsed/Refractory Advanced Multiple Myeloma (mm)

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs PF-06863135 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top